A Phase 1, Open-label, Fixed-Sequence Trial to Evaluate the Effect of Carbamazepine on the Single-Dose Pharmacokinetics of Darigabat in Healthy Adult Participants
Latest Information Update: 18 Aug 2023
Price :
$35 *
At a glance
- Drugs Darigabat (Primary) ; Carbamazepine
- Indications Anxiety disorders; Epilepsy; Panic disorder; Seizures
- Focus Pharmacokinetics
- Sponsors Cerevel Therapeutics
- 02 Aug 2023 Status changed from active, no longer recruiting to completed.
- 23 Jun 2023 Planned End Date changed from 31 Oct 2023 to 27 Jun 2023.
- 23 Jun 2023 Planned primary completion date changed from 31 May 2023 to 27 Jun 2023.